Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

Sean McBride,Nancy Y. Lee,David G. Pfister,Eric J. Sherman,C. Jillian Tsai,Jahan Aghalar,Juliana Eng,Wanqing Iris Zhi,Daniel C. McFarland,Loren S. Michel,Lara Dunn,Alan Loh Ho,Nadeem Riaz

Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

2019

Sean McBride
Nancy Y. Lee
David G. Pfister
Eric J. Sherman
C. Jillian Tsai
Jahan Aghalar
Juliana Eng
Wanqing Iris Zhi
Daniel C. McFarland
Loren S. Michel
Lara Dunn
Alan Loh Ho
Nadeem Riaz

6063Background: A minority of patients with M1 HNSCC respond to the anti-programmed death (PD-1) monoclonal antibody, Nivolumab (Nivo). We sought to determine biomarker predictors of outcome to Niv...

Keywords:

Oncology
Randomized controlled trial
Head and neck squamous-cell carcinoma
Nivolumab
Pathology
Radiation therapy
Biomarker (medicine)
Internal medicine
Medicine
stereotactic body radiotherapy
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations